New IMiD on the block
Mené sur 73 patients atteints d’un lymphome non hodgkinien à cellules B réfractaire ou récidivant, cet essai de phase I évalue la dose maximale tolérée de l’avadomide en combinaison avec l’obinutuzumab, et analyse les caractéristiques pharmacocinétiques et pharmacodynamiques de cette combinaison (durée médiane de suivi : 253 jours)
In The Lancet Haematology, Jean-Marie Michot and colleagues describe the results of a phase 1b study investigating the safety and tolerability of the combination of avadomide, a novel oral cereblon-modulating agent, and obinutuzumab for the treatment of relapsed refractory non-Hodgkin lymphomas. The phase 1 escalation part of the study defined the recommended phase 2 dose of avadomide in combination with obinutuzumab, and the analysis of the expansion cohort showed preliminary activity of the combination, which was mainly seen in patients with follicular lymphoma. 1 Although these results come from a very early phase of clinical development, they stimulate reflection on the recent and future evolution of lymphoma treatment and on the possible role played by avadomide.
The Lancet Haematology , commentaire, 2019